{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:11:55Z","timestamp":1783977115518,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFE0106900"],"award-info":[{"award-number":["2021YFE0106900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["CIFMS 2022-I2M-1-022"],"award-info":[{"award-number":["CIFMS 2022-I2M-1-022"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270144"],"award-info":[{"award-number":["82270144"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Haihe Laboratory of Cell Ecosystem Innovation Fund","award":["22HHXBSS00039"],"award-info":[{"award-number":["22HHXBSS00039"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07028-7","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T19:33:46Z","timestamp":1778096026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance"],"prefix":"10.1007","volume":"105","author":[{"given":"Changwen","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueshen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"7028_CR1","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.01692","volume":"37","author":"S Jeha","year":"2019","unstructured":"Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E et al (2019) Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J Clin Oncol 37:3377\u20133391. https:\/\/doi.org\/10.1200\/JCO.19.01692","journal-title":"J Clin Oncol"},{"key":"7028_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood.2020010438","volume":"138","author":"J Tang","year":"2021","unstructured":"Tang J, Yu J, Cai J, Zhang L, Hu S, Gao J et al (2021) Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation. Blood 138:331\u2013343. https:\/\/doi.org\/10.1182\/blood.2020010438","journal-title":"Blood"},{"key":"7028_CR3","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","volume":"27","author":"G Basso","year":"2009","unstructured":"Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D et al (2009) Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow. J Clin Oncol 27:5168\u20135174. https:\/\/doi.org\/10.1200\/JCO.2008.20.8934","journal-title":"J Clin Oncol"},{"key":"7028_CR4","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","volume":"126","author":"MJ Borowitz","year":"2015","unstructured":"Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL et al (2015) Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232. Blood 126:964\u2013971. https:\/\/doi.org\/10.1182\/blood-2015-03-633685","journal-title":"Blood"},{"key":"7028_CR5","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH et al (2017) Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. JAMA Oncol 3:e170580. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0580","journal-title":"JAMA Oncol"},{"key":"7028_CR6","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/S1470-2045(21)00328-4","volume":"22","author":"W Yang","year":"2021","unstructured":"Yang W, Cai J, Shen S, Gao J, Yu J, Hu S et al (2021) Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol 22:1322\u20131332. https:\/\/doi.org\/10.1016\/S1470-2045(21)00328-4","journal-title":"Lancet Oncol"},{"issue":"10","key":"7028_CR7","first-page":"1002","volume":"60","author":"J Tang","year":"2022","unstructured":"Tang J, Shen S, Zhu X, Li CK, Cai J, Yu J et al (2022) Report of Chinese Children\u2019s Cancer Group acute lymphoblastic leukemia 2015 multicenter study. Zhonghua Er Ke Za Zhi 60(10):1002\u20131010. https:\/\/rs.yiigle.com\/cmaid\/1427987.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"7028_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1182\/hematology.2019000017","volume":"2019","author":"A Winters","year":"2019","unstructured":"Winters A, Gore L (2019) Moving immunotherapy into the front line in ALL. Hematology 2019:209\u2013217. https:\/\/doi.org\/10.1182\/hematology.2019000017","journal-title":"Hematology"},{"key":"7028_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2411680","volume":"392","author":"S Gupta","year":"2025","unstructured":"Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL et al (2025) Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med 392:875\u2013891. https:\/\/doi.org\/10.1056\/NEJMoa2411680","journal-title":"N Engl J Med"},{"key":"7028_CR10","doi-asserted-by":"publisher","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","volume":"120","author":"MS Topp","year":"2012","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, Degenhard E, Goebeler M-E, Klinger M et al (2012) Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120:5185\u20135187. https:\/\/doi.org\/10.1182\/blood-2012-07-441030","journal-title":"Blood"},{"key":"7028_CR11","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131:1522\u20131531. https:\/\/doi.org\/10.1182\/blood-2017-08-798322","journal-title":"Blood"},{"key":"7028_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ et al (2021) Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA 325:833. https:\/\/doi.org\/10.1001\/jama.2021.0669","journal-title":"JAMA"},{"key":"7028_CR13","unstructured":"USFood and Drug Administration (2018) FDA granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia. Updated March 29, 2018. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-blinatumomab-blincyto-amgen-inc-treatment-adult-and-pediatric. Accessed 5 Feb 2026"},{"key":"7028_CR14","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS et al (2012) Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood 119:6226\u20136233. https:\/\/doi.org\/10.1182\/blood-2012-01-400515","journal-title":"Blood"},{"key":"7028_CR15","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, G\u00f6kbuget N, Goebeler M, Klinger M, Neumann S et al (2011) Targeted Therapy With the T-Cell\u2013Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival. J Clin Oncol 29:2493\u20132498. https:\/\/doi.org\/10.1200\/JCO.2010.32.7270","journal-title":"J Clin Oncol"},{"key":"7028_CR16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T et al (2022) T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood 140:1104\u20131118. https:\/\/doi.org\/10.1182\/blood.2022015956","journal-title":"Blood"},{"key":"7028_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1182\/blood.2020006287","volume":"137","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Aldoss I, Qu C, Crawford JC, Gu Z, Allen EK et al (2021) Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood 137:471\u2013484. https:\/\/doi.org\/10.1182\/blood.2020006287","journal-title":"Blood"},{"key":"7028_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s43058-022-00310-5","volume":"3","author":"C Duffy","year":"2022","unstructured":"Duffy C, Santana V, Inaba H, Jeha S, Pauley J, Sniderman L et al (2022) Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol. Implement Sci Commun 3:62. https:\/\/doi.org\/10.1186\/s43058-022-00310-5","journal-title":"Implement Sci Commun"},{"key":"7028_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1159\/000542060","volume":"148","author":"J Kong","year":"2024","unstructured":"Kong J, Miao W, Lu J, Liu Y, Kong X, Qiu H et al (2024) Shorter Duration of Blinatumomab Administration to 14 Days Has Same Efficacy and Safety Profile in Treatment of Relapsed\/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study. Acta Haematol 148:437\u2013442. https:\/\/doi.org\/10.1159\/000542060","journal-title":"Acta Haematol"},{"key":"7028_CR20","doi-asserted-by":"publisher","first-page":"e70515","DOI":"10.1002\/cam4.70515","volume":"13","author":"J Yin","year":"2024","unstructured":"Yin J, Cai X, Qian B, Liu Y, Li D (2024) Short-Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed\/Refractory B\u2010Cell Acute Lymphoblastic Leukemia: A Retrospective Single\u2010Center Study. Cancer Med 13:e70515. https:\/\/doi.org\/10.1002\/cam4.70515","journal-title":"Cancer Med"},{"key":"7028_CR21","doi-asserted-by":"publisher","first-page":"1187607","DOI":"10.3389\/fped.2023.1187607","volume":"11","author":"J Xie","year":"2023","unstructured":"Xie J, Liu S, Zhou M, Wang Y, He H, Xiao P et al (2023) Short-course blinatumomab for refractory\/relapse precursor B acute lymphoblastic leukemia in children. Front Pediatr 11:1187607. https:\/\/doi.org\/10.3389\/fped.2023.1187607","journal-title":"Front Pediatr"},{"key":"7028_CR22","doi-asserted-by":"publisher","first-page":"e7679617","DOI":"10.1097\/01.HS9.0000972496.76796.17","volume":"7","author":"C Xue","year":"2023","unstructured":"Xue C, Wu C, Yang W, Zou Y, Guo Y, Chen Y et al (2023) P1402: Infusion of 14 days blinatunomab in combination with chemotherapy for 46-day MRD+ pediatric B-all patients in intermediate\/high-risk group results in MRD conversion. HemaSphere 7:e7679617. https:\/\/doi.org\/10.1097\/01.HS9.0000972496.76796.17","journal-title":"HemaSphere"},{"key":"7028_CR23","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2024-202203","volume":"144","author":"C Xue","year":"2024","unstructured":"Xue C, Zhang Y, Wu C, Yang W, Zou Y, Guo Y et al (2024) Short-Term Blinatumomab Combined with Early Chemotherapy for Newly Diagnosed Pediatric Patients with B-Cell Acute Lymphoblastic Leukemia. Blood 144:2824\u20132824. https:\/\/doi.org\/10.1182\/blood-2024-202203","journal-title":"Blood"},{"key":"7028_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN et al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transpl 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transpl"},{"key":"7028_CR25","doi-asserted-by":"publisher","first-page":"841117","DOI":"10.3389\/fonc.2022.841117","volume":"12","author":"SHC Baumeister","year":"2022","unstructured":"Baumeister SHC, Mohan GS, Elhaddad A, Lehmann L (2022) Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. Front Oncol 12:841117. https:\/\/doi.org\/10.3389\/fonc.2022.841117","journal-title":"Front Oncol"},{"key":"7028_CR26","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1038\/s41375-024-02386-5","volume":"38","author":"J Stutterheim","year":"2024","unstructured":"Stutterheim J, Van Der Waarden R, De Groot-Kruseman HA, Sonneveld E, De Haas V, Dandis R et al (2024) Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic. leukemia? Leuk 38:2376\u20132381. https:\/\/doi.org\/10.1038\/s41375-024-02386-5","journal-title":"leukemia? Leuk"},{"key":"7028_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.seminhematol.2020.06.003","volume":"57","author":"J Bartram","year":"2020","unstructured":"Bartram J, Patel B, Fielding AK (2020) Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. Semin Hematol 57:142\u2013148. https:\/\/doi.org\/10.1053\/j.seminhematol.2020.06.003","journal-title":"Semin Hematol"},{"key":"7028_CR28","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","volume":"36","author":"J Zuna","year":"2022","unstructured":"Zuna J, Hovorkova L, Krotka J, Koehrmann A, Bardini M, Winkowska L et al (2022) Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia 36:2793\u20132801. https:\/\/doi.org\/10.1038\/s41375-022-01668-0","journal-title":"Leukemia"},{"key":"7028_CR29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285119","author":"J Li","year":"2024","unstructured":"Li J, Lu A, Gao Y, Wan Y, Wang J, Zhang J et al (2024) Minimal residual disease monitoring in childhood Philadelphia-positive acute lymphoblastic leukemia: prognostic significance and correlation between multiparameter flow cytometry and real-time quantitative polymerase chain reaction. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2024.285119","journal-title":"Haematologica"},{"key":"7028_CR30","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1182\/blood.V84.7.2221.2221","volume":"84","author":"C Mackall","year":"1994","unstructured":"Mackall C, Fleisher T, Brown M, Magrath I, Shad A, Horowitz M et al (1994) Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84:2221\u20132228. https:\/\/doi.org\/10.1182\/blood.V84.7.2221.2221","journal-title":"Blood"},{"key":"7028_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/1096-911X(20010201)36","volume":"36","author":"B Moritz","year":"2001","unstructured":"Moritz B, Eder J, Meister B, Heitger A (2001) Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy. Med Pediatr Oncol 36:283\u2013289. https:\/\/doi.org\/10.1002\/1096-911X(20010201)36:2%253C283::AID-MPO1066%253E3.0.CO;2-8","journal-title":"Med Pediatr Oncol"},{"key":"7028_CR32","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1007\/s00432-022-04039-5","volume":"148","author":"J Kauer","year":"2022","unstructured":"Kauer J, M\u00e4rklin M, Pfl\u00fcgler M, H\u00f6rner S, Hinterleitner C, Tandler C et al (2022) BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. J Cancer Res Clin Oncol 148:2759\u20132771. https:\/\/doi.org\/10.1007\/s00432-022-04039-5","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07028-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07028-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07028-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:02:09Z","timestamp":1783976529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07028-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["7028"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07028-7","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical Committee approval code: IIT2021056-EC-3.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained from the parents, guardians, or patients, as appropriate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"ChiCTR2100053318.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial information"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"305"}}